The comparison efficacy and safety of topical caspofungin ?.5% and topical voriconazole 1% in fungal keratitis

Phase 2

Recruiting

• Conditions: FUNGAL KERATITIS.; Mycoses, Disorders of sclera, cornea, iris and ciliary body, Disorders of sclera and cornea in diseases classified elsewhere; B35-B49,H1

• Registration Number: IRCT20231219060471N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Smear or culture positive fungal keratitis or fungal keratitis with negative smear or culture which is diagnosed by confocal scan
Corneal ulcer with a 5mm maximum diameter, involving 4 mm of the center of the cornea, and extending less than 5?% of the corneal stromal depth

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy and safety of topical caspofungin 0.5% and topical voriconazole 1% will be compared in treating fungal keratitis. Clinical response, scar formation, corneal scar size, visual acuity outcomes, and size and depths of corneal infiltration will also be evaluated. Timepoint: An ophthalmic examination will be conducted daily during hospitalization, on the 7th, 14th, and 30th days, as well as on the 3rd month. Method of measurement: A clinical examination will be conducted by an expert ophthalmologist. The examination will involve the use of a slit-lamp biomicroscopy to detect clinical response and measure the size and depth of infiltration using a caliper. The size and depth of the corneal scar will also be detected with a slit lamp and measured using a caliper. All clinical responses will be recorded by slit-lamp photography in each examination.